Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC
Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC
Active, not recruiting · NCT03769103 · Registry updated 2024-10-31Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC | Brain Metastases, Neoplasms by Site, Thoracic Neoplasms, brain disorder, bronchial neoplasm, bronchogenic carcinoma, central nervous system cancer, central nervous system disorder, lung disorder, lung neoplasm, neoplasm, nervous system disorder, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 2 | 2024-10-31 | NCT03769103 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AstraZeneca | 806 |
| British Columbia Cancer Agency | 58 |
| Princess Margaret Hospital, Canada | 28 |
| Sunnybrook Health Sciences Centre | 193 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| BC Cancer, Vancouver Centre | Vancouver | Canada | 1 |
| Princess Margaret Hospital | Toronto | Canada | 8 |
| Sunnybrook Health Sciences Centre | Toronto | Canada | 23 |